GGrantIndex
Sort

326,823 grants matching clinical trial

Clinical validity and utility of genomic targeted chemoprevention of PCa

$2,006,440
Jianfeng Xu · Wake Forest University Health Sciences · UC2 · FY2010 · CA

Biology and Therapy of High Risk Neuroblastoma

$2,006,380
Robert C Seeger · Children'S Hospital Of Los Angeles · P01 · FY2012 · CA

Quantitative systems biology of glioblastoma cells and their interactions with the neuronal and immunological milieu

$2,006,283
Forest M White · Massachusetts Institute Of Technology · U54 · FY2023 · CA

Targeting sensory ganglia and glial signaling for the treatment of acute and chronic pain

$2,006,250
Temugin Berta · University Of Cincinnati · R01 · FY2019 · NS

Center for Translational Viral Oncology (CTVO)

$2,006,137
Krzysztof Reiss · Lsu Health Sciences Center · P20 · FY2019 · GM

SPORE: Brain Tumore SPORE Grant

$2,006,093
Mitchel S. Berger · University Of California, San Francisco · P50 · FY2016 · CA

Clinical Training in Rheumatology

$2,005,975
Daniel Kastner · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIE · FY2009 · AR

The Immunobiology of Marrow Allografts for Leukemia

$2,005,952
Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA

Coordinating Center for CALERIE

$2,005,824
James Rochon · Duke University · U01 · FY2008 · AG

Surgery, Immunology and Immunotherapy of Human Cancer

$2,005,765
Donald L Morton · Saint John'S Cancer Institute · P01 · FY2009 · CA

Improving the safety and efficacy of cell therapies

$2,005,762
Malcolm K Brenner · Baylor College Of Medicine · U54 · FY2007 · HL

Center for Dietary Supplements and Inflammation

$2,005,567
Prakash S. Nagarkatti · University Of South Carolina At Columbia · P20 · FY2012 · GM

Developing Information Infrastructure Focused on Cancer Comparative Effectiveness

$2,005,467
David Alan Fenstermacher · H. Lee Moffitt Cancer Ctr & Res Inst · RC2 · FY2009 · CA

ACCORD

$2,005,398
David C Goff · Wake Forest University Health Sciences · N01 · FY2009 · HL

Physical Fitness as an Objective Biomarker for AD/ADRD Risk Modification

$2,005,396
Qing Zeng · George Washington University · RF1 · FY2020 · AG

An Open Source Research Permissions Framework for South Carolina

$2,004,583
Jay Moskowitz · University Of South Carolina At Columbia · RC2 · FY2010 · LM

Race / Ethncicity, Hypertension and Prevention of VCID and Stroke after Intracerebral Hemmorrhage

$2,004,572
Jonathan Rosand · Massachusetts General Hospital · R01 · FY2025 · NS

UCLA SPOTRIAS CENTER APPLICATION RENEWAL-PROGRAM PROJECT

$2,004,544
Jeffrey L Saver · University Of California Los Angeles · P50 · FY2012 · NS

GHESKIO Clinical Trials Unit

$2,004,533
Jean William Pape · Gheskio Center · UM1 · FY2022 · AI

Stroke Disparities Program

$2,004,423
Chelsea M Kidwell · Georgetown University · U54 · FY2009 · NS

Vaccine Treatment and Evaluation Units: Phase I Schistosomiasis Vaccine Clinical Trial

$2,004,304
Wendy Keitel · Baylor College Of Medicine · N01 · FY2017 · AI

A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia

$2,004,198
David G. Nathan · Dana-Farber Cancer Inst · P50 · FY2016 · HL

Community-Based VCT: Zimbabwe

$2,004,140
Stephen F Morin · University Of California, San Francisco · U01 · FY2008 · MH

THE COMPARATIVE EFFECTIVENESS OF TELEMEDICINE TO DETECT DIABETIC RETINOPATHY

$2,003,926
Thomas Mark Becker · Oregon Health & Science University · U48 · FY2010 · DP

MOTOR-Maternal Oral Therapy to Reduce Obstetric Risk

$2,003,919
University Of North Carolina Chapel Hill · U01 · FY2003 · DE